Ionis Pharmaceuticals (IONS) Tops Q4 EPS by 45c ; Offers Guidance

Ionis Pharmaceuticals (NASDAQ: IONS) reported Q4 EPS of ($0.66), $0.45 better than the analyst estimate of ($1.11). Revenue for the quarter came in at $227 million versus the consensus estimate of $135.58 million.

GUIDANCE:

Ionis Pharmaceuticals sees FY2025 revenue of ~$600 million, versus the consensus of $677.1 million.

For earnings history and earnings-related data on Ionis Pharmaceuticals (IONS) click here.

You May Also Be Interested In

• Magnificent 7 stocks lose $2.3 trillion in June
• Aptevo gets $1.5M grant to advance APVO451 cancer therapy
• Ionis Pharmaceuticals (IONS) PT Raised to $130 at H.C. Wainwright